Aberdeen Group plc Grows Stock Position in Tarsus Pharmaceuticals, Inc. $TARS

Aberdeen Group plc boosted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 18.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 61,597 shares of the company’s stock after acquiring an additional 9,728 shares during the period. Aberdeen Group plc’s holdings in Tarsus Pharmaceuticals were worth $2,495,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in TARS. Paradigm Biocapital Advisors LP increased its stake in Tarsus Pharmaceuticals by 3.1% during the first quarter. Paradigm Biocapital Advisors LP now owns 2,610,197 shares of the company’s stock worth $134,086,000 after acquiring an additional 78,301 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 5.3% during the 1st quarter. Vanguard Group Inc. now owns 2,226,595 shares of the company’s stock worth $114,380,000 after purchasing an additional 111,433 shares during the period. Lord Abbett & CO. LLC increased its position in shares of Tarsus Pharmaceuticals by 4.0% during the 1st quarter. Lord Abbett & CO. LLC now owns 1,331,701 shares of the company’s stock worth $68,409,000 after purchasing an additional 51,714 shares during the last quarter. Driehaus Capital Management LLC purchased a new stake in Tarsus Pharmaceuticals in the 1st quarter valued at about $36,876,000. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in Tarsus Pharmaceuticals in the 1st quarter valued at about $26,199,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $55.37, for a total transaction of $332,220.00. Following the sale, the chief executive officer owned 812,106 shares of the company’s stock, valued at approximately $44,966,309.22. This represents a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William J. Phd Link sold 27,116 shares of Tarsus Pharmaceuticals stock in a transaction on Monday, September 8th. The shares were sold at an average price of $57.00, for a total value of $1,545,612.00. Following the completion of the transaction, the director owned 143,332 shares of the company’s stock, valued at approximately $8,169,924. This trade represents a 15.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,116 shares of company stock valued at $2,177,832. Insiders own 8.97% of the company’s stock.

Analyst Ratings Changes

TARS has been the subject of several research analyst reports. Zacks Research raised shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $66.67.

Tarsus Pharmaceuticals Stock Down 2.7%

Shares of NASDAQ:TARS opened at $72.93 on Friday. The firm has a market capitalization of $3.08 billion, a PE ratio of -31.30 and a beta of 0.81. Tarsus Pharmaceuticals, Inc. has a 1 year low of $35.84 and a 1 year high of $76.81. The company has a debt-to-equity ratio of 0.22, a current ratio of 5.26 and a quick ratio of 5.21. The firm’s 50-day moving average is $58.73 and its two-hundred day moving average is $49.01.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%. The business had revenue of $102.66 million during the quarter, compared to analyst estimates of $95.81 million. Analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.